Vivoryon Therapeutics N.V./€VVY
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. is a clinical-stage biotechnology company specializing in the development of small molecule medicines targeting post-translational modifications implicated in various diseases. Its lead candidate, varoglutamstat, is an oral inhibitor of glutaminyl cyclases (QPCT and QPCTL) with potential applications in inflammatory and fibrotic diseases, neurodegenerative conditions, and cancer. Originally focused on Alzheimer's disease, the company shifted its strategic emphasis to kidney diseases in 2024 after observing significant improvements in kidney function during clinical trials. Headquartered in Halle (Saale) and Munich, Germany, Vivoryon has expanded its intellectual property portfolio, including a U.S. patent granted in May 2025 for varoglutamstat, providing exclusivity through 2044. The company's unique approach centers on modulating disease-related protein activity and stability through targeted enzyme inhibition.
Ticker
€VVY
Sector
Primary listing
AEX
Employees
14
Headquarters
Website
VVY Metrics
BasicAdvanced
€44M
-
-€0.48
1.96
-
Price and volume
Market cap
€44M
Beta
1.96
52-week high
€3.00
52-week low
€1.38
Average daily volume
36K
Financial strength
Current ratio
4.037
Quick ratio
3.839
Long term debt to equity
0.346
Total debt to equity
2.263
Interest coverage (TTM)
-745.59%
Profitability
EBITDA (TTM)
-12.587
Management effectiveness
Return on assets (TTM)
-67.68%
Return on equity (TTM)
-145.47%
Valuation
Price to book
13.82
Price to tangible book (TTM)
18.71
Price to free cash flow (TTM)
-4.245
Free cash flow yield (TTM)
-23.56%
Free cash flow per share (TTM)
-0.398
Growth
Earnings per share change (TTM)
-61.20%
3-year earnings per share growth (CAGR)
-10.20%
10-year earnings per share growth (CAGR)
-14.39%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vivoryon Therapeutics N.V. stock?
Vivoryon Therapeutics N.V. (VVY) has a market cap of €44M as of September 16, 2025.
What is the P/E ratio for Vivoryon Therapeutics N.V. stock?
The price to earnings (P/E) ratio for Vivoryon Therapeutics N.V. (VVY) stock is 0 as of September 16, 2025.
Does Vivoryon Therapeutics N.V. stock pay dividends?
No, Vivoryon Therapeutics N.V. (VVY) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Vivoryon Therapeutics N.V. dividend payment date?
Vivoryon Therapeutics N.V. (VVY) stock does not pay dividends to its shareholders.
What is the beta indicator for Vivoryon Therapeutics N.V.?
Vivoryon Therapeutics N.V. (VVY) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.